Dementia

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

“If we can show that serotonin loss over time is directly involved in the transition from mild cognitive impairment to Alzheimer disease, recently developed antidepressant medications may be an effective way to improve memory deficits and depressive symptoms and, thus, may be a powerful way forward to slow disease progression.”

Two phase 3 trials were conducted to assess the clinical and biological effects as well as the safety of gantenerumab in individuals with mild cognitive impairment or mild dementia due to AD. Here's what you need to know.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

AVP-786, a drug to treat agitation associated with Alzheimer disease dementia, failed to meet the primary efficacy endpoint in a phase 3 clinical trial.

From pain and suicidality in patients with depression to digital mental health interventions for adolescents with eating disorders, here are highlights from the week in Psychiatric Times.

From the impact of BMI on clinical features of bipolar disorder to FDA approval of the first integrated TMS system for MDD and OCD, here are highlights from the week in Psychiatric Times.

How efficacious is brexpiprazole as a treatment for agitation associated with Alzheimer disease?

Clinicians must feel knowledgeable and masterful in incorporating lifestyle and integrative therapies targeting nutrition, stress reduction, normalization of sleep, aerobic and mindful exercise, and meaningful activities that add joy and life to years, and not just years to life.

Here are highlights from some of the year’s top features in Psychiatric Times from throughout 2023.

In this CME, learn more about the pathophysiology of HIV-associated neurocognitive disorder and to review the research and various tools used to aid in the diagnosis.

Here are some updates from the world of psychiatry throughout the month of November.

What is new in research on psychedelics?

From neurological abnormalities in first-episode psychosis to psychiatric boarding in emergency departments, here are highlights from the week in Psychiatric Times.

What is new in research on dementia?

New positive data for brexpiprazole, the first and only treatment approved to treat agitation associated with dementia due to Alzheimer disease.

What is new in research on sleep?

The drug’s developer announced that the FDA has made 2 clarifying revisions.

What is new in research on psychiatric care for Latinx patient populations?

What is new in research on attention-deficit/hyperactivity disorder?

From a look at adolescent substance use to special challenges in treating borderline personality disorder during the perinatal period, here are highlights from the week in Psychiatric Times.

“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”

Trial results underscore the importance of early diagnosis and treatment in patients with Alzheimer disease.

"There is clearly a large unmet need not only to improve our treatment of AD, but to provide treatment options for all the dementias."

From the FDA traditional approval of Leqembi to an examination of how we can improve mental health care for women of color, here are highlights from the week in Psychiatric Times.

Announcement follows the FDA’s accelerated approval and unanimous endorsement of the drug earlier this year.

From substance use among adolescents and young adults to managing behavioral and psychological symptoms of dementia, here are highlights from the week in Psychiatric Times.

Recognition is the first and most important step to treating behavioral and psychological symptoms of dementia.

From the relationship between social media and self-diagnosis to the FDA approval of the first treatment for agitation associated with Alzheimer disease dementia, here are highlights from the week in Psychiatric Times.

Brexpiprazole has been approved by the US Food and Drug Administration for the treatment of agitation associated with Alzheimer disease dementia.